Satish Mehta
#244CEO and Managing Director
75
Age
44y
Exp
44y
Tenure
6/10
Risk
🎓 B.Sc. Chemistry · Pune University
📜 PGDM · Indian Institute of Management, Ahmedabad
🏛️ IIM
CompensationTBP
Personality
6
Open
8
Cons
5
Extr
5
Agre
3
Neur
Emcure Pharma
Healthcare · Large Cap
High Growth · Founder-Centric
About
Satish Mehta is the CEO and Managing Director of Emcure Pharma, a Large Cap company in the Healthcare sector with a market cap of ₹29K Cr. A Pragmatic leader with 44 years of experience, he is known for intuition-driven decision-making and organic builder strategy. He has methodically steered Emcure through complex R&D cycles and geographic scaling, emphasizing consistent, steady growth over speculative ventures.
FAQ
What is Satish Mehta's leadership style?
Satish Mehta is classified as a Pragmatic leader. He is intuition-driven in decision-making, with a empire expander motivation and startup-speed pace of execution.
What is Satish Mehta's educational background?
Satish Mehta holds a B.Sc. Chemistry from Pune University and a PGDM from Indian Institute of Management, Ahmedabad.
Who is the CEO of Emcure Pharma?
Satish Mehta is the CEO and Managing Director of Emcure Pharma. He has been with the company for 44 years and in the current role for 44 years.
Leadership DNA
ArchetypePragmatic
MotivationEmpire Expander
CrisisRevenue Hunter
DecisionIntuition-Driven
GrowthOrganic Builder
PeopleRelationship Led
InnovationFast-Follower
PaceStartup-Speed
PurposePurpose-Blended
CustomerB2B-Enterprise
EmployerDemanding Machine
BrandTechnical-Expert
FocusMarket Expansion
OrientationDeep Specialist
Leadership Evidence
“He has methodically steered Emcure through complex R&D cycles and geographic scaling, emphasizing consistent, steady growth over speculative ventures.”
⚡ Crisis●●●●○
Emcure consistently expanded its portfolio and market reach even during challenging regulatory environments by focusing on high-growth therapeutic segments like HIV and women's health.
🎯 Motivation●●●●○
Satish Mehta has aggressively scaled Emcure from a local player into a global entity with presence in over 70 countries through consistent capacity expansion and market penetration.
👥 People●●●○○
The company maintains a culture characterized by long-term stability in its core management team and a focus on deep-rooted professional relationships built over decades.
📈 Growth●●●●○
Emcure's growth has been primarily driven by its own R&D capabilities and the development of a vast, complex manufacturing infrastructure rather than large-scale M&A.
💡 Innovation●●●●○
Emcure excels at developing complex generics and differentiated formulations in competitive therapeutic segments like cardiology and HIV, scaling them efficiently after market entry.
🏃 Pace●●●○○
The company maintains a high-growth trajectory and rapid product development cycle characteristic of a promoter-led firm aggressively capturing market share in the specialty pharma space.
🌱 Purpose●●●○○
The company maintains a strong focus on healthcare access through its diverse product portfolio and active engagement in corporate social responsibility initiatives focused on community health.
🏷️ Brand●●●●○
Emcure is recognized for its strong R&D capabilities and technical proficiency in manufacturing complex pharmaceutical products, positioning it as a reliable technical partner in the healthcare ecosystem.
🤝 Customer●●●●●
Emcure primarily operates through a B2B model, supplying pharmaceutical products to hospitals, medical practitioners, and international institutional partners rather than direct-to-consumer retail.
💼 Employer●●●○○
As a high-growth, founder-led pharmaceutical company, it maintains a performance-oriented culture focused on aggressive sales targets and operational efficiency.
📋 Mandate
Sustained success in the competitive pharmaceutical landscape demands continuous R&D and portfolio expansion into niche therapeutic segments.
🏢 Culture●●●○○
High promoter holding with active involvement of the CEO in strategic expansion.
Financials
Revenue FY25₹8K Cr
PAT FY25₹681 Cr
Rev CAGR 5Y10.6%
OPM13.9%
NPM8.7%
ROE15.3%
ROCE19.5%
P/E31.3
Fwd P/E23.7
P/B5.7
D/E34
Promoter81.7%
Institutional5.1%
Mkt Cap₹29K Cr
Compensation
To Be Published
Data being verified from audited reports
